{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T04:17:36Z","timestamp":1774844256715,"version":"3.50.1"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2023,10,24]],"date-time":"2023-10-24T00:00:00Z","timestamp":1698105600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p>Mutations in the <jats:italic>CLN5<\/jats:italic> gene cause the fatal, pediatric, neurodegenerative disease CLN5 neuronal ceroid lipofuscinosis. Affected children suffer progressive neuronal loss, visual failure and premature death. Presently there is no treatment. This study evaluated dual intracerebroventricular (ICV) and intravitreal (IVT) administration of a self-complementary adeno-associated viral vector encoding ovine <jats:italic>CLN5<\/jats:italic> (scAAV9\/oCLN5) into CLN5 affected sheep (CLN5<jats:sup>\u2212\/\u2212<\/jats:sup>) at various disease stages. CLN5 disease progression was slowed in pre-symptomatic sheep who received a moderate dose of scAAV9\/oCLN5, whilst a higher ICV dose treatment in early and advanced symptomatic animals delayed or halted disease progression. Intracranial (brain) volume loss was attenuated in all treatment cohorts, and visual function was also sustained in both the early and advanced symptomatic treated sheep over the 24-month duration of the study. Robust CLN5 protein expression was detected throughout the brain and spinal cord, and improvements in central nervous system and retinal disease correlates were observed. These findings hold translational promise for extending and improving the quality of life in both pre-symptomatic and symptomatic CLN5 patients, and prompted the initiation of the first in-human Phase I\/II clinical trial testing ICV\/IVT administration of scAAV9 encoding human <jats:italic>CLN5<\/jats:italic> (<jats:ext-link>https:\/\/clinicaltrials.gov\/<\/jats:ext-link>; NCT05228145).<\/jats:p>","DOI":"10.3389\/fphar.2023.1212235","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T06:14:56Z","timestamp":1698214496000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy of dual intracerebroventricular and intravitreal CLN5 gene therapy in sheep prompts the first clinical trial to treat CLN5 Batten disease"],"prefix":"10.3389","volume":"14","author":[{"given":"Samantha J.","family":"Murray","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin P.","family":"Wellby","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Graham K.","family":"Barrell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katharina N.","family":"Russell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ashley R.","family":"Deane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R.","family":"Wynyard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Gray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David N.","family":"Palmer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nadia L.","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2023,10,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1016\/0887-8994(92)90032-T","article-title":"Jansky-Bielschowsky variant disease: CT, MRI, and SPECT findings","volume":"8","author":"Autti","year":"1992","journal-title":"Pediatr. Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"4735","DOI":"10.1007\/s00018-021-03813-x","article-title":"A lysosomal enigma CLN5 and its significance in understanding neuronal ceroid lipofuscinosis","volume":"78","author":"Basak","year":"2021","journal-title":"Cell. Mol. Life Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1136\/bmjqs-2014-003499","article-title":"Finding patients before they crash: the next major opportunity to improve patient safety","volume":"67","author":"Bates","year":"2015","journal-title":"J. Stat. Softw."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1323","DOI":"10.1016\/j.mri.2012.05.001","article-title":"3D Slicer as an image computing platform for the quantitative imaging network","volume":"30","author":"Federov","year":"2012","journal-title":"Magn. Reson. Imaging"},{"key":"B5","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.nbd.2007.09.006","article-title":"A new large animal model of CLN5 neuronal ceroid lipofuscinosis in Borderdale sheep is caused by a nucleotide substitution at a consensus splice site (c.571+1G>A) leading to excision of exon 3","volume":"29","author":"Frugier","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"B6","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.nbd.2003.12.019","article-title":"The mouse ortholog of the neuronal ceroid lipofuscinosis CLN5 gene encodes a soluble lysosomal glycoprotein expressed in the developing brain","volume":"16","author":"Holmberg","year":"2004","journal-title":"Neurobiol. Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1212\/wnl.55.4.579","article-title":"Phenotype-genotype correlation in eight patients with Finnish variant late infantile NCL (CLN5)","volume":"55","author":"Holmberg","year":"2000","journal-title":"Neurology"},{"key":"B8","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1080\/00480169.2002.36311","article-title":"Neuronal ceroid-lipofuscinosis in Borderdale sheep","volume":"50","author":"Jolly","year":"2002","journal-title":"N. Z. Vet. J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/hmg\/ddh312","article-title":"A mouse model for Finnish variant late infantile neuronal ceroid lipofuscinosis, CLN5, reveals neuropathology associated with early aging","volume":"13","author":"Kopra","year":"2004","journal-title":"Hum. Mol. Genet."},{"key":"B10","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1089\/hum.2011.026","article-title":"Lentiviral-mediated gene transfer to the sheep brain: Implications for gene therapy in Batten disease","volume":"22","author":"Linterman","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1212228","DOI":"10.3389\/fgene.2023.1212228","article-title":"Long-term safety and dose escalation of intracerebroventricular CLN5 gene therapy in sheep supports clinical translation for CLN5 Batten disease","volume":"14","author":"Mitchell","year":"","journal-title":"Front. Genet."},{"key":"B12","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1002\/dneu.22918","article-title":"Characterization of neuropathology in ovine CLN5 and CLN6 neuronal ceroid lipofuscinoses (Batten disease)","volume":"83","author":"Mitchell","year":"","journal-title":"Dev. Neurobiol."},{"key":"B13","doi-asserted-by":"publisher","first-page":"2366","DOI":"10.1016\/j.ymthe.2018.07.015","article-title":"Longitudinal In\u00a0Vivo Monitoring of the CNS Demonstrates the Efficacy of Gene Therapy in a Sheep Model of CLN5 Batten Disease","volume":"26","author":"Mitchell","year":"2018","journal-title":"Mol. Ther."},{"key":"B14","doi-asserted-by":"publisher","first-page":"3670","DOI":"10.1038\/s41598-022-07612-7","article-title":"Natural history of retinal degeneration in ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses","volume":"12","author":"Murray","year":"2022","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"108600","DOI":"10.1016\/j.exer.2021.108600","article-title":"Intravitreal gene therapy protects against retinal dysfunction and degeneration in sheep with CLN5 Batten disease","volume":"207","author":"Murray","year":"2021","journal-title":"Exp. Eye Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1016\/j.nbd.2005.01.025","article-title":"Glial activation spreads from specific cerebral foci and precedes neurodegeneration in presymptomatic ovine neuronal ceroid lipofuscinosis (CLN6)","volume":"20","author":"Oswald","year":"2005","journal-title":"Neurobiol. Dis."},{"key":"B17","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1146\/annurev-med-122313-085916","article-title":"Lysosomal Storage Diseases: From pathophysiology to therapy","volume":"66","author":"Parenti","year":"2015","journal-title":"Annu. Rev. Med."},{"key":"B18","unstructured":"R: A Language and Environment for Statistical Computing2021"},{"key":"B19","doi-asserted-by":"publisher","first-page":"e01096","DOI":"10.1002\/brb3.1096","article-title":"Computed tomography provides enhanced techniques for longitudinal monitoring of progressive intracranial volume loss associated with regional neurodegeneration in ovine neuronal ceroid lipofuscinoses","volume":"8","author":"Russell","year":"2018","journal-title":"Brain Behav."},{"key":"B20","doi-asserted-by":"publisher","first-page":"107188","DOI":"10.1016\/j.dib.2021.107188","article-title":"Electroretinography data from ovine models of CLN5 and CLN6 neuronal ceroid lipofuscinoses","volume":"37","author":"Russell","year":"2021","journal-title":"Data Br."},{"key":"B21","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.ymthe.2006.01.006","article-title":"Gene therapy for lysosomal storage diseases","volume":"13","author":"Sands","year":"2006","journal-title":"Mol. Ther."},{"key":"B22","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.tibtech.2008.02.002","article-title":"Biomedical applications of sheep models: from asthma to vaccines","volume":"26","author":"Scheerlinck","year":"2008","journal-title":"Trends Biotechnol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1111\/j.1750-3639.2004.tb00077.x","article-title":"Hippocampal pathology in the human neuronal ceroid-lipofuscinoses: distinct patterns of storage deposition, neurodegeneration and glial activation","volume":"14","author":"Tyynel\u00e4","year":"2004","journal-title":"Brain Pathol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1097\/00005072-199704000-00005","article-title":"Variant late infantile neuronal ceroid-lipofuscinosis: pathology and biochemistry","volume":"56","author":"Tyynel\u00e4","year":"1997","journal-title":"J. Neuropathol. Exp. Neurol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ymgme.2004.06.019","article-title":"Electroretinographic and clinicopathologic correlations of retinal dysfunction in infantile neuronal ceroid lipofuscinosis (infantile Batten disease)","volume":"83","author":"Weleber","year":"2004","journal-title":"Mol. Genet. Metab."},{"key":"B26","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1002\/(SICI)1097-0185(199704)247:4<542:AID-AR13>3.0.CO;2-P","article-title":"Anatomy of the sheep spine and its comparison to the human spine","volume":"247","author":"Wilke","year":"1997","journal-title":"Anat. Rec."},{"key":"B27","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1080\/10790268.2016.1222475","article-title":"An ovine model of spinal cord injury","volume":"40","author":"Wilson","year":"2017","journal-title":"J. Spinal Cord. Med."},{"key":"B28","doi-asserted-by":"publisher","first-page":"565","DOI":"10.1212\/WNL.0b013e3181cff70d","article-title":"CLN5 mutations are frequent in juvenile and late-onset non-Finnish patients with NCL","volume":"74","author":"Xin","year":"2010","journal-title":"Neurology"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1212235\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T06:14:59Z","timestamp":1698214499000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2023.1212235\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,24]]},"references-count":28,"alternative-id":["10.3389\/fphar.2023.1212235"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2023.1212235","relation":{},"ISSN":["1663-9812"],"issn-type":[{"value":"1663-9812","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,24]]},"article-number":"1212235"}}